“None of the Italian companies is comparable in size, for example, to those of the companies that produce anti-Covid vaccines today. But their research and development is extremely intense”. This was explained by Lucia Aleotti, shareholder and board member of Menarini, speaking at the online Talk Sanità, organized by RCS Academy, on the theme ‘Strategies for reforming the system and winning the pandemic’.
Aleotti recalled the partnership of Menarini with the Toscana Life Sciences Foundation, a Foundation that “carried out the research for the new anti-Covid monoclonal antibody and that sought Menarini as a company capable of fine-tuning the production process and large-scale production of a molecule of the type biopharmaceutical, and he found Menarini ready why the company has been working for years on monoclonal antibodies for the treatment of tumors“. But, added Aleotti, in Italy there are many cases of this type:” we can mention Chiesi’s excellence in respiratory diseases. Or Dompé, who has developed a drug for the treatment of a biotechnological ocular disease, based on the studies of the Nobel laureate Rita Levi Montalcini, registered and welcomed with the ‘red carpets’ by the American regulatory authority. An all-Italian invention and production “.
Then, “although the size of the pharmaceutical sector with Italian capital is not comparable to that of the big international companies, the dynamism is extreme. And there are even smaller realities from which very interesting discoveries often emerge “, he concluded.